Skip to main content

By Biocat

Ysios Capital Partners has announced the closing of the first round of funding, for a value of €2 millions, in Inbiomotion, a spin-off of the Institute for Research in Biomedicine (IRB Barcelona) and the Catalan Institution for Research and Advanced Studies (ICREA). Vila Casas Private Foundation and JVRisk Technologies have also invested.

Inbiomotion, based in the Barcelona Science Park and founded by Dr. Roger Gomis, is carrying out a trial to validate the capacity of its marker to predict future bone metastasis using technology developed by IRB Barcelona. The investment raised will go to fund the validation of this marker through various clinical trials in Barcelona and England, and to advance development through regulatory approval. As of today, it has been validated with more than 900 patient samples in two different trials carried out with independent techniques (gene expression and immunohistochemistry), with a negative predictive value of 95%.

No tools currently exist to predict a cancer patient’s risk of bone metastasis. This would represent a shift in clinical practice, allowing for improved quality of life and management of cancer patients, as well as more efficient use of economic resources in the healthcare system.

“These investors, beyond contributing financial capital, give the company essential know-how in business development, allowing the company to position itself and gain visibility in the sector,” explained Roger Gomis.

Director of IRB Barcelona Joan J. Guinovart remarked, “This is the first time Ysios has invested in a biotechnology company that has come out of a public basic research center. This shows that we are doing frontier science, which is attractive to investors and can help improve quality of life for everyone.”

Sign up for our newsletters

Stay up-to-date on the latest news, events and trends in the BioRegion.